18/08/2026 Biocon announced US FDA approval of Yesintek® single dose prefilled autoinjector Abcuro announced a $66 million series D financing to advance ulviprubart in inclusion body myositis Biocon announced US FDA approval of Yesintek® single dose prefilled autoinjector (Ref) Biocon announced that its US Subsidiary had received supplemental US FDA approval for Yesintek® (ustekinumab-kfce) as a single-dose prefilled autoinjector. The approval covered 45 mg/0.5 mL and 90 mg/m

27/07/2026 Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline InnoCare's fadeucravacitinib met it primary endpoint in Phase 3 Psoriasis study Jacobio dosed the first patient in China in Phase 2a trial of JAB-8263 for Rheumatoid arthritis Bambusa Therapeutics reported preliminary Proof-of-concept data for BTT001 in Atopic Dermatitis Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline (Ref) Argenx announced that the compa

11/06/2026 Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA Climb Bio announced initial Phase 1b data for budoprutug in ITP at EHA Congress 2026 Takeda’s Zasocitinib significantly outperformed deucravacitinib in a head-to-head Phase 3 Psoriasis Study Nipocalimab demonstrated a durable hemoglobin response and rapid onset of effect in a Phase 2/3 study in wAIHA (Ref) Johnson & Johnson presented results from the Phase

28/03/2026 Biogen announced Phase 2 results for litifilimab for CLE Results from Sanofi’s Phase 3 studies in AD were presented AAD Alumis announced Phase 3 data for envudeucitinib for plaque psoriasis Incyte announced Phase 3 data for povorcitinib for HS Biogen announced Phase 2 results for litifilimab for CLE ( Ref ) Biogen announced positive results from part A of its Phase2/3 AMETHYST/ NCT05531565 study, which evaluated litifilimab (BDCA2) for the treatment of patients w

18/03/2026 J&J announced FDA approval for icotrokinra for adult and pediatric patients with moderate to severe plaque psoriasis J&J announced FDA approval for icotrokinra for adult and pediatric patients with moderate to severe plaque psoriasis ( Ref ) Johnson & Johnson announced that the US FDA had approved ICOTYDE™ (icotrokinra; IL-23 receptor antagonist) for the treatment of adults and pediatric patients aged 12 years and older who weighed at least 40 kg with moderate to s